PL1708722T3 - Nowa śródmiąższowa terapia dla natychmiastowego złagodzenia objawów i przewlekła terapia śródmiąższowego zapalenia pęcherza - Google Patents

Nowa śródmiąższowa terapia dla natychmiastowego złagodzenia objawów i przewlekła terapia śródmiąższowego zapalenia pęcherza

Info

Publication number
PL1708722T3
PL1708722T3 PL05712839T PL05712839T PL1708722T3 PL 1708722 T3 PL1708722 T3 PL 1708722T3 PL 05712839 T PL05712839 T PL 05712839T PL 05712839 T PL05712839 T PL 05712839T PL 1708722 T3 PL1708722 T3 PL 1708722T3
Authority
PL
Poland
Prior art keywords
therapy
interstitial
novel
symptom relief
chronic
Prior art date
Application number
PL05712839T
Other languages
English (en)
Inventor
C Lowell Parsons
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34826198&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1708722(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ California filed Critical Univ California
Publication of PL1708722T3 publication Critical patent/PL1708722T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
PL05712839T 2004-01-28 2005-01-27 Nowa śródmiąższowa terapia dla natychmiastowego złagodzenia objawów i przewlekła terapia śródmiąższowego zapalenia pęcherza PL1708722T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54018604P 2004-01-28 2004-01-28
PCT/US2005/003542 WO2005072751A1 (en) 2004-01-28 2005-01-27 Novel interstitial therapy for immediate symptom relief and chronic therapy in interstitial cystitis
EP05712839.9A EP1708722B1 (en) 2004-01-28 2005-01-27 Novel interstitial therapy for immediate symptom relief and chronic therapy in interstitial cystitis

Publications (1)

Publication Number Publication Date
PL1708722T3 true PL1708722T3 (pl) 2014-10-31

Family

ID=34826198

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05712839T PL1708722T3 (pl) 2004-01-28 2005-01-27 Nowa śródmiąższowa terapia dla natychmiastowego złagodzenia objawów i przewlekła terapia śródmiąższowego zapalenia pęcherza

Country Status (10)

Country Link
US (4) US7414039B2 (pl)
EP (2) EP1708722B1 (pl)
AU (1) AU2005209322B2 (pl)
CA (1) CA2554489A1 (pl)
DK (1) DK1708722T3 (pl)
ES (1) ES2493626T3 (pl)
PL (1) PL1708722T3 (pl)
PT (1) PT1708722E (pl)
SI (1) SI1708722T1 (pl)
WO (1) WO2005072751A1 (pl)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1507543A4 (en) 2002-05-09 2006-07-26 Cambridgemed Inc PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF WOOD WITH BLOOD PLASMA OR SERUM
KR20140002082A (ko) * 2005-01-14 2014-01-07 유리젠, 인코포레이티드 하부 요로 장애 치료용 키트 및 개선된 조성물
JP5265359B2 (ja) 2005-08-11 2013-08-14 マサチューセッツ インスティテュート オブ テクノロジー 膀胱内薬物送達デバイスおよび方法
US7323184B2 (en) 2005-08-22 2008-01-29 Healagenics, Inc. Compositions and methods for the treatment of wounds and the reduction of scar formation
US20070172508A1 (en) * 2006-01-26 2007-07-26 Paul Zupkas Transluminal drug delivery methods and devices
DE102006060953A1 (de) * 2006-12-12 2008-08-07 Farco-Pharma Gmbh Pharmazeutische Zubereitung für die Behandlung entzündlicher Erkrankungen des Urogenitaltraktes
EP2607477B1 (en) 2007-05-03 2020-09-23 The Brigham and Women's Hospital, Inc. Multipotent stem cells and uses thereof
US8574567B2 (en) * 2007-05-03 2013-11-05 The Brigham And Women's Hospital, Inc. Multipotent stem cells and uses thereof
US8828452B2 (en) * 2007-05-22 2014-09-09 Glenn Abrahmsohn Method for pain control
US9586035B2 (en) 2007-12-11 2017-03-07 Massachusetts Institute Of Technology Implantable drug delivery device and methods for treatment of the bladder and other body vesicles or lumens
EA201170297A1 (ru) 2008-08-09 2011-08-30 Массачусетс Инститьют Оф Текнолоджи Имплантируемое устройство для доставки лекарственных средств и способ лечения мужской мочеполовой системы и окружающих тканей
FR2938187B1 (fr) † 2008-11-07 2012-08-17 Anteis Sa Composition injectable a base d'acide hyaluronique ou l'un de ses sels, de polyols et de lidocaine, sterilisee a la chaleur
WO2010085589A2 (en) 2009-01-22 2010-07-29 G&H Brands Llc Desensitizing drug product
CN102470237A (zh) * 2009-06-26 2012-05-23 塔里斯生物医药公司 用于可植入药物递送装置的固体药物片剂
ES2634505T3 (es) * 2009-08-13 2017-09-28 Lubris Llc Tratamiento de PRG4 para la cistitis intersticial
US9017312B2 (en) * 2009-09-10 2015-04-28 Taris Biomedical Llc Implantable device for controlled drug delivery
CN106913902A (zh) 2009-11-09 2017-07-04 聚光灯技术合伙有限责任公司 多糖基水凝胶
CN102695501A (zh) 2009-11-09 2012-09-26 聚光灯技术合伙有限责任公司 碎裂水凝胶
AU2011213175A1 (en) * 2010-02-04 2014-02-20 Michael M. Goldberg Use of oral heparin preparations to treat urinary tract diseases and conditions
EP3711750B1 (en) 2010-08-05 2023-09-06 TARIS Biomedical LLC Implantable drug delivery devices for genitourinary sites
KR20140049964A (ko) * 2011-01-06 2014-04-28 씨. 로웰 파슨즈 국부 마취제, 헤파리노이드 및 버퍼를 포함하는 조성물의 제조 방법
US9114111B2 (en) 2011-01-10 2015-08-25 Allergan, Inc. Methods for sustained treatment of bladder pain and irritative voiding
AU2012211960B2 (en) 2011-02-04 2016-12-01 Taris Biomedical Llc Implantable device for controlled release of low solubility drug
US9849086B2 (en) 2012-03-19 2017-12-26 Nanologix Research, Inc. Method and composition for treating cystitis
EP2948154A4 (en) * 2013-01-28 2016-09-14 Urigen Pharmaceuticals Inc STABLE COMPOSITIONS WITH HEPARINOID, A DIRECT ANESTHETIC, AND A BUFFER
PT2968880T (pt) 2013-03-15 2025-07-07 Taris Biomedical Llc Dispositivos de aplicação de fármaco com componente permeável a fármaco
CN113413393B (zh) 2013-08-19 2025-03-04 塔里斯生物医药公司 多单元药物递送装置和方法
JP2017512757A (ja) * 2014-02-24 2017-05-25 ウリゲン ファーマシューティカルズ、インコーポレイテッド 経口投与するためのペントサンポリ硫酸塩の組成物および使用の方法
RU2586285C1 (ru) * 2015-03-24 2016-06-10 Общество с ограниченной ответственностью "ФармСинергия" Водная композиция для инстилляций в мочевой пузырь
KR102658706B1 (ko) 2015-04-23 2024-04-17 타리스 바이오메디컬 엘엘씨 약물-투과성 성분을 구비한 약물 전달 장치 및 방법
US10004824B2 (en) 2015-05-11 2018-06-26 Laboratoires Vivacy Compositions comprising at least one polyol and at least one anesthetic
AU2018223811B2 (en) 2017-02-27 2021-05-27 Urigen N.A. Treatment of lower urinary tract epithelium with glucagon like peptide 2
WO2018191412A1 (en) * 2017-04-12 2018-10-18 Urigen Pharmaceuticals, Inc. Article of manufacture comprising local anesthetic, buffer, and glycosaminoglycan in syringe with improved stability
RU2648443C1 (ru) * 2017-05-10 2018-03-26 Федеральное государственное бюджетное учреждение "Новосибирский научно-исследовательский институт туберкулеза" Министерства здравоохранения Российской Федерации (ФГБУ "ННИИТ" Минздрава России) Способ профилактики обострения посткоитального цистита
ES2968164T3 (es) * 2019-04-26 2024-05-08 Tcm Biotech Int Corp Composición farmacéutica para la prevención de infección urinaria recurrente
HUP2000094A1 (hu) * 2020-03-12 2021-06-28 Lovasz Sandor Dr Gyógyászati és/vagy gyógyszerkészítmény intravezikális instillációra, elõállításuk és alkalmazásuk
US20220273698A1 (en) * 2019-07-18 2022-09-01 Gabor RENY Medicinal and/or pharmaceutical compositions for intravesical instillation, preparation and use thereof
WO2021011566A1 (en) * 2019-07-18 2021-01-21 Parsons C Lowell Alkalization of urinary bladder wall prior to treatment with intravesical heparin and alkalinized lidocaine to enhance relief of bladder pain symptoms
HU231553B1 (hu) * 2020-04-29 2024-11-28 Lovász Sándor Dr. Vizelet lúgosító gyógyászati és/vagy gyógyszerkészítmény interstitialis cystitis / hólyagfájdalom szindróma (IC/BPS)orális kezelésére és formulálása
WO2025015011A1 (en) * 2023-07-10 2025-01-16 Nevakar Injectables Inc. Bupivacaine compositions and methods

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4268518A (en) * 1979-05-19 1981-05-19 Fisons Limited Method of treating cystitis
US4460360A (en) 1982-08-30 1984-07-17 Finegold Aaron N Urethral anesthetic devices
US5037810A (en) 1987-03-17 1991-08-06 Saliba Jr Michael J Medical application for heparin and related molecules
US4879282A (en) 1987-03-17 1989-11-07 Saliba Jr Michael J Medical application for heparin and related molecules
US5196405A (en) 1987-07-08 1993-03-23 Norman H. Oskman Compositions and methods of treating hemorrhoids and wounds
US5104856A (en) * 1990-11-09 1992-04-14 Uab Research Foundation Heparan sulfate biosynthesis primers
US5137528A (en) 1990-11-26 1992-08-11 Crose Virginia W Ampoule for administering a liquid local anaesthetic
AU2441592A (en) * 1991-08-08 1993-03-02 Leigh D. Segel Fluorocarbon blood substitute
GB9310095D0 (en) 1993-05-17 1993-06-30 Zeneca Ltd Therapeutic compounds
US5749845A (en) 1995-01-25 1998-05-12 Iotek, Inc. Delivering an agent to an organ
ZA962455B (en) * 1995-03-31 1996-10-02 B Eugene Guthery Fast acting and persistent topical antiseptic
US5972326A (en) * 1995-04-18 1999-10-26 Galin; Miles A. Controlled release of pharmaceuticals in the anterior chamber of the eye
WO1998002186A1 (en) 1996-07-11 1998-01-22 Farmarc Nederland B.V. Inclusion complex containing indole selective serotonin agonist
US5879282A (en) * 1997-01-21 1999-03-09 Cordis A Johnson And Johnson Company Catheter having an expandable radioactive source
US6159944A (en) 1998-02-27 2000-12-12 Synchroneuron, Llc Method for treating painful conditions of the anal region and compositions therefor
US6083933A (en) 1999-04-19 2000-07-04 Stellar International Inc. Treatment of cystitis-like symptoms with chondroitin sulfate following administration of a challenge solution
RU2147876C1 (ru) * 1999-07-08 2000-04-27 Государственное учреждение Межотраслевой научно-технический комплекс "Микрохирургия глаза" Фармацевтическая композиция для обезболивания в офтальмологии
US20040047910A1 (en) 2000-07-07 2004-03-11 Christian Beckett Suppository and composition comprising at least one polyethylene glycol
US6648863B2 (en) 2000-09-20 2003-11-18 Scimed Life Systems, Inc. Apparatus and methods for treating the urinary bladder
EP1609468A3 (en) 2000-11-22 2006-01-25 Rxkinetix, Inc. A composition on the basis of a sulfur-containing antioxidant and its use for the manufacture of a medicament for treating mucositis
EP1372629A2 (en) * 2000-12-08 2004-01-02 Pieter Theo Ernst Therapeutic treatment
US20040142968A1 (en) 2003-01-17 2004-07-22 Donald Price Method and kit for treating lower bowel pain
AU2004207010A1 (en) 2003-01-30 2004-08-12 Dynogen Pharmaceuticals, Inc. Methods of treating lower urinary tract disorders using sodium channel modulators
US20040161476A1 (en) 2003-02-19 2004-08-19 Hahn Sungtack Samuel Cystitis treatment with high dose chondroitin sulfate
US20040248979A1 (en) 2003-06-03 2004-12-09 Dynogen Pharmaceuticals, Inc. Method of treating lower urinary tract disorders
KR20140002082A (ko) * 2005-01-14 2014-01-07 유리젠, 인코포레이티드 하부 요로 장애 치료용 키트 및 개선된 조성물

Also Published As

Publication number Publication date
AU2005209322B2 (en) 2011-05-19
US20080300219A1 (en) 2008-12-04
WO2005072751A1 (en) 2005-08-11
EP1708722A1 (en) 2006-10-11
US7414039B2 (en) 2008-08-19
US20190321391A1 (en) 2019-10-24
CA2554489A1 (en) 2005-08-11
US20050234013A1 (en) 2005-10-20
EP1708722B1 (en) 2014-05-21
EP1708722A4 (en) 2009-04-01
US20170007638A1 (en) 2017-01-12
SI1708722T1 (sl) 2014-10-30
AU2005209322A1 (en) 2005-08-11
DK1708722T3 (da) 2014-08-25
US9486474B2 (en) 2016-11-08
EP2813231A1 (en) 2014-12-17
PT1708722E (pt) 2014-09-12
ES2493626T3 (es) 2014-09-12

Similar Documents

Publication Publication Date Title
SI1708722T1 (sl) Nova intersticijska terapija za takojšnje simptome sprostitve in kronična terapija pri intersticijskem cistitisu
IL180759A0 (en) Indazoles useful in treating cardiovascular diseases
EP2038041A4 (en) THERAPEUTIC COMPOUNDS AND THEIR USE AGAINST CANCER
IL182652A0 (en) Nitrobenzindoles and their use in cancer therapy
GB0416857D0 (en) Electronic financial transactions
GB0703229D0 (en) Improvements in and relatingto neuro stimulation
GB0400700D0 (en) Compounds useful in therapy
GB0523576D0 (en) Drug composition and its use in therapy
ZA200702093B (en) Arene ruthenium (II) compounds and their use in cancer therapy
ZA200709542B (en) Combination therapy in the treatment of cancer
GB0428522D0 (en) Retrotransposon inhibition in therapy
GB0428170D0 (en) Mono and Combination Therapy
GB0607946D0 (en) Mono and combination therapy
GB0607949D0 (en) Mono and combination therapy
IL193663A0 (en) Thiadiazole compounds and their use in phototherapy
EP1827417A4 (en) PHOTODYNAMIC THERAPY WITH IMPROVED OCCLUSIVE EFFECT
GB0425854D0 (en) Therapeutic treatment
GB2434547B (en) Improvements in and relating to peripheral neurostimulation
GB0700827D0 (en) Hai-1 and Hai-2 in cancer therapy
EP1997487A4 (en) PRODUCT USED IN THE PREVENTION AND TREATMENT OF CARDIAC DISEASES, CANCER AND INFLAMMATORY DISEASES
GB2417688B (en) Improvements in and relating to neurostimulation
EP1810673A4 (en) THERAPEUTIC AGENT FOR SUB-MUCOUS INTERSTITIAL CYSTOPATHY
GB0408752D0 (en) Therapeutic treatment
EP1778228A4 (en) THERAPEUTIC CONNECTION AND TREATMENTS
GB0512551D0 (en) Methods and therapeutic treatments